SBIR/STTR Research Award

Isoporous Silicon Nanomembranes for Purification of Therapeutic Viruses

Award identifier b3f0e26290bb79697e5edcd0a6e386fad2a2c1a268b0cea9e1183b55f5a08458Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$225,000

Program and phase

SBIR · Phase I

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Simpore Inc.
Proposal award date
2018-03-01
Contract end date
2019-08-31
UEI
NYNDZ3F46K36
Solicitation number
PA17-302
Topic code
400

Research abstract

Abstract Viruses engineered for gene therapy and the destruction of tumor cellsoncolytic virusesare a growing medical market$ B bywith profound implications for human healthTo comply with FDA regulationsmost drug products remove microbial contaminants with sterile filtration as a final stepIn the case of virusesthe broad pore sizes and high internal surface areas of commercial sterile filtration membranes result in massive product lossConsequentlyGMP paradigms for the production of medical grade virus must implement aseptic practices at every step of productionSiMPore uses silicon based manufacturing to create ultrathinnm thickmembranes with precision pore sizes and more thanorders of magnitude less internal surface area than conventional sterile filtersThis proposal investigates the hypothesis that these distinctive properties will enable sterile filtration of virus with less thanlossIn Aimwe will develop and characterize ultrathin membranes with a high density ofm slit poresThis pore size matches the average pore size of commercial sterile filtersbut with a dramatic reduction in thickness and internal surface areaFunctional characterization will include sievingburst pressuresand hydraulic permeability testingIn Aimwe will evaluate SiMPore membranes as sterile filters by comparing loss and capacity directly tocommercial sterile membrane filtersWith success in Phase ISiMPoreandapos s membranes will be scaled up from chip based to sheet based formats and used in diafiltration modules as final processing step in actual viral manufacturing processes during Phase II Narrative The manufacture of viruses for gene therapy or as anti cancer agents cannot use sterile filtration as a final production step because of massive titer losswith conventional polymer membranesSiMPore uses silicon manufacturing to produce ultrathin membranes with precise pore sizes that should enable the filtration of virus with minimal lossThis project will develop SiMPore membranes for the sterile filtration of virus and compare performance directly against three commercial membrane filters

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

12 SBIR/STTR records share this UEI (2010–2022). Reported award amounts total $5,643,223. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.